Treatment modalities using various HDAC inhibitors, which can enhance synaptic plasticity, learning and memory, have emerged as potential new strategies for therapeutic intervention in neurodegenerative diseases, including AD, Huntington’s disease, and Parkinson’s disease (Konsoula and Barile, 2012). Here, HDAC9 is linked to juvenile Huntington disease.